Search Results - therapeutic+substance

250 Results Sort By:
Adoptive Proinflammatory Myeloid Cell Therapy for Cancer
Unmet Need: Prostate cancer is one of the most commonly diagnosed cancers in the male population; roughly one out of ten men will be diagnosed at some point in their lives. Despite extending survival, androgen depravation therapy invariably leads to the development of lethal castration resistant prostate cancer. Similarly, pancreatic ductal carcinoma...
Published: 5/2/2024   |   Inventor(s): Alan Friedman
Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics, Whole cell
Category(s): Technology Classifications > Therapeutic Modalities > Cell Therapies, Clinical and Disease Specializations > Oncology
Prodrug for Immunological and Oncological Therapy
Unmet NeedApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several major drawbacks for each method. Stem cell transplants can...
Published: 5/2/2024   |   Inventor(s): Barbara Slusher, Rana Rais, Franco D'alessio, Pavel Majer, Marcela Krecmerova, Srinivasan Yegnasubramanian
Keywords(s): Blood Cancer, Cancers, Disease Indication, Inflammatory Disorders, Respiratory Infections, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Transplants
Category(s): Clinical and Disease Specializations > Oncology > Hematologic Malignancies, Clinical and Disease Specializations > Transplantation, Technology Classifications > Therapeutic Modalities > Small Molecules
SYNGAP antisense oligonucleotide as therapy for human cognitive disorders
Unmet Need: Recent human genetic studies have suggested that mutations in the SYNGAP1 gene are linked to intellectual disability (ID), autism spectrum disorders (ASD), neurodevelopmental disorders, high rates of epilepsy, and schizophrenia. SYNGAP1 is a gene that encodes SynGAP, a GTPase-activating protein that is highly enriched in nerve cells in the...
Published: 5/3/2024   |   Inventor(s): Richard Huganir, Ingie Hong, Yoichi Araki
Keywords(s): Biologics, CNS and Neurological Disorders, Cognitive Impairment, Disease Indication, Gene Therapy, Nucleic Acid, Single, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations > Psychiatry > Autism Spectrum Disorder, Clinical and Disease Specializations > Psychiatry > ADHD, Clinical and Disease Specializations > Psychiatry > Mood Disorders, Technology Classifications > Therapeutic Modalities > Gene Therapies
Cell-Permeable Protein Therapeutic for Pain and Itch
Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...
Published: 5/2/2024   |   Inventor(s): Hao-Jui Weng, Xinzhong Dong
Keywords(s): Biologics, Biomarker, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Pain, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Pain > Chronic Pain
Treatment of Irritable Bowel Syndrome with Molybdenum
Unmet NeedIrritable Bowel Syndrome is a chronic and incurable gastrointestinal disorder that affects 3-20% of Americans depending on certain sociocultural and comorbid factors. A poorly understood condition, current treatments consist of antispasmodics, antidiarrheals, and dietary restrictions. Unable to alleviate all its symptoms, researchers are in...
Published: 5/2/2024   |   Inventor(s): Pankaj Pasricha, Lian Sheng Liu, Qian Li, Alfred Spormann
Keywords(s): Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease (IBD), Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Gastroenterology > Irritable Bowel Disease
Inhibition of rip kinases for treating neurodegenerative disorders
Unmet NeedNeurodegenerative disorders are a heterogeneous group that includes Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), dementia, and Huntington’s disease. These disorders result from progressive degeneration of the structure, function, and network of neurons in the central nervous...
Published: 5/2/2024   |   Inventor(s): Seulki Lee, Han Seok Ko, Ted Dawson, Martin Pomper, Donghoon Kim, Yumin Oh, Seung-Hwan Kwon, Yong Joo Park
Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Neurodegenerative Diseases, Parkinson's Disease, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease
Novel Therapeutic Drug for Multiple Sclerosis
INVENTION NOVELTY This molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in MS. Currently, there are no MS drugs in the market...
Published: 5/2/2024   |   Inventor(s): Paul Kim, Michael Kornberg, Peter Calabresi, Solomon Snyder
Keywords(s): Chronic Inflammatory Diseases, CNS and Neurological Disorders, Disease Indication, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Autoimmunity, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Inflammation, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Inflammation > Chronic Inflammatory Diseases, Clinical and Disease Specializations > Neurology > Multiple Sclerosis, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Immunology
Selective Targeting of a Novel Protective Anti-inflammatory Receptor in Human Mitochondria and its Role in Preserving Mitochondrial Functions
Unmet NeedAccording to WHO, over one billion people worldwide are living with elevated blood pressure which may lead to a range of adverse health conditions that cause ~1,100 deaths per day. Many current high blood pressure therapies focus on angiotensin receptor blocking drugs. Unfortunately, adverse events (e.g., renal dysfunction, hyperkalemia, and...
Published: 5/2/2024   |   Inventor(s): Andrew Cheetham, Peter Abadir, Jeremy Walston, Honggang Cui
Keywords(s): Antagonists/Inhibitors, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities
In vivo and in vitro Role of Lactosylceramide Synthase (LCS) in Angiogenesis and LCS (B1, 4GalT-V) as a Bio-marker for Human Colon Cancer
Description:   C10539: Use of Biomarker for Colon Cancer Diagnosis Value Proposition: ADVANTAGES • Colon cancer biomarker is directly included in panels of biomarkers for use in needle biopsies of colon tissue for early detection and diagnosis. • Colon cancer is the second largest mortality after cardiovascular disease. 90% of colorectal cancers...
Published: 5/2/2024   |   Inventor(s): Subroto Chatterjee
Keywords(s): Antagonists/Inhibitors, Biomarker, Cancers, Clinical Diagnostics, Colorectal Cancer, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Colorectal Cancer
Transgenic Fungi that Kill Malaria Parasites in Mosquitoes
Invention novelty: This material is a transgenic fungus which targets the sporozoites that cause malaria in the salivary glands of mosquitoes. The fungus is taken up by direct contact with the mosquito and inhibits Plasmodium development. Value Proposition: Unmodified, Metarhizium anisopliae kills mosquitoes slowly. If mosquitoes are infected by the...
Published: 5/2/2024   |   Inventor(s): Raymond St. Leger, Angray Kang, Weiguo Fang, Marcelo Jacobs-Lorena
Keywords(s): Biologics, Disease Indication, Disease Management System, Healthcare Management, Infectious Diseases, Malaria, Operations Management, Parasitic Infections, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Technology Classifications > Computers, Electronics & Software > Clinical Management, Technology Classifications > Computers, Electronics & Software > Healthcare IT, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Computers, Electronics & Software, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections
1 2 3 4 5 6 7 8 9 10 ...
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum